Evidence of reduced coronary artery disease risk for apolipoprotein 2/3 heterozygotes

Author： Mamotte C.D.S.   Burke V.   Taylor R.R.   van Bockxmeer F.M.  

Publisher： Elsevier

ISSN： 0953-6205

Source： European Journal of Internal Medicine, Vol.13, Iss.4, 2002-06, pp. : 250-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apolipoprotein A-I Mimetic Peptides for the Treatment of Coronary Artery Disease

By  

Current Cardiology Reviews, Vol. 1, Iss. 1, 2005-01 ,pp. : 81-84

Bentham Science Publishers

Access to resources Recommend Favorite

Evidence against hypercoagulability in coronary artery disease

By Gorog P.   Ridler C.D.   Rees G.M.   Kovacs I.B.  

Thrombosis Research, Vol. 79, Iss. 4, 1995-08 ,pp. : 377-385

Elsevier

Access to resources Recommend Favorite

Myeloproliferative syndromes and the associated risk of coronary artery disease

By Ganti A.K.   Potti A.   Koka V.K.   Pervez H.   Mehdi S.A.  

Thrombosis Research, Vol. 110, Iss. 2, 2003-05 ,pp. : 83-86

Elsevier

Access to resources Recommend Favorite

Antihypertensive Drugs and Coronary Artery Disease: Evidence from Controlled Trials

By Verdecchia Paolo   Angeli Fabio  

High Blood Pressure & Cardiovascular Prevention, Vol. 12, Iss. 3, 2005-01 ,pp. : 119-124

Adis International

Access to resources Recommend Favorite

The association of serum chemerin level with risk of coronary artery disease in Chinese adults

By Yan Qun  

Endocrine, Vol. 41, Iss. 2, 2012-04 ,pp. : 281-288

Springer Publishing Company

Access to resources Recommend Favorite